1. Home
  2. VERX vs TSHA Comparison

VERX vs TSHA Comparison

Compare VERX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Inc.

VERX

Vertex Inc.

HOLD

Current Price

$12.18

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.59

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERX
TSHA
Founded
1978
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
VERX
TSHA
Price
$12.18
$5.59
Analyst Decision
Buy
Strong Buy
Analyst Count
12
8
Target Price
$24.25
$11.63
AVG Volume (30 Days)
1.3M
2.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.56
EPS
N/A
N/A
Revenue
$748,444,000.00
$9,773,000.00
Revenue This Year
$12.78
N/A
Revenue Next Year
$11.61
$1,152.42
P/E Ratio
$302.25
N/A
Revenue Growth
12.25
17.28
52 Week Low
$10.59
$2.25
52 Week High
$37.77
$7.30

Technical Indicators

Market Signals
Indicator
VERX
TSHA
Relative Strength Index (RSI) 43.57 47.71
Support Level $12.16 $5.27
Resistance Level $12.54 $6.01
Average True Range (ATR) 0.67 0.35
MACD -0.12 -0.04
Stochastic Oscillator 10.87 49.33

Price Performance

Historical Comparison
VERX
TSHA

About VERX Vertex Inc.

Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: